Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs BONTRIL PDM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,Relief of nasal congestion associated with allergic rhinitis or common cold
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine p H).
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Desloratadine is metabolized to 3-hydroxydesloratadine via CYP2C8 and CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Desloratadine: 83-87% bound (primarily albumin); pseudoephedrine sulfate: minimal binding, ~20% bound.
98% bound to albumin.
Desloratadine: ~16.8 L/kg (high Vd, extensive tissue distribution); pseudoephedrine sulfate: ~2.6-3.5 L/kg (moderate Vd).
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Desloratadine: 76% (oral); pseudoephedrine sulfate: ~100% (extended-release formulation).
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Contraindicated in GFR < 30 m L/min. For GFR 30-59 m L/min: not recommended due to lack of data. For GFR ≥ 60 m L/min: no adjustment needed.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
No specific Child-Pugh based recommendations. Use with caution in severe hepatic impairment; desloratadine clearance reduced.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Not approved for pediatric patients; safety and efficacy not established in children <12 years. For ≥12 years: same as adult.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Use with caution due to increased sensitivity, risk of CNS effects, and potential renal impairment. Consider starting at lower doses; avoid in patients with severe renal impairment.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
None.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
Severe hypertension and/or tachycardia,Cardiovascular disease including ischemic heart disease and arrhythmias,Increased intraocular pressure,Diabetes mellitus,Thyroid dysfunction,Prostatic hypertrophy/urinary retention,Renal impairment,Seizure disorders,Use in elderly patients
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension,Coronary artery disease,Use of MAO inhibitors within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
Avoid alcohol as it may increase sedative effects. Limit or avoid caffeine-containing foods/drinks (coffee, tea, soda, chocolate) to reduce risk of nervousness, insomnia, and tachycardia. No specific food interactions with desloratadine; pseudoephedrine is not significantly affected by food.
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester; possible uterine vasoconstriction in second/third trimester. Overall, avoid in first trimester; use only if benefit outweighs risk in second/third trimester.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
Desloratadine: low excretion into breast milk; M/P ratio not established. Pseudoephedrine: small amounts in milk; peak milk concentration at 2-4 hours; M/P ratio 1.7-3.5. May cause irritability or sleep disturbance in infants; reduce breast milk production. Not recommended during breastfeeding.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
No pharmacokinetic data in pregnancy; standard dosing not recommended due to risk profile. Use only if clearly needed and under medical supervision.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
Desloratadine is a long-acting antihistamine; pseudoephedrine sulfate is a nasal decongestant. The 24-hour formulation provides extended relief. Use with caution in patients with hypertension, hyperthyroidism, or benign prostatic hyperplasia. Avoid in narrow-angle glaucoma. Monitor for insomnia and nervous system stimulation. May cause dry mouth and urinary retention.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
Take one tablet daily with a full glass of water; do not crush or chew.,Avoid taking with other sympathomimetic amines (e.g., pseudoephedrine, phenylephrine) to prevent excessive cardiovascular stimulation.,May cause drowsiness; avoid driving or operating heavy machinery until you know how the medication affects you.,Limit caffeine intake to reduce additive stimulant effects.,Do not use if you have severe hypertension, coronary artery disease, or are taking MAOIs currently or within past 14 days.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
"Ketazolam, a benzodiazepine, can cause central nervous system (CNS) depression. Desloratadine, a nonsedating antihistamine, has a low potential for CNS depression at therapeutic doses. However, when combined with benzodiazepines, the risk of additive CNS depressant effects increases, potentially leading to excessive sedation, dizziness, and impaired psychomotor function. This interaction is particularly relevant in patients with hepatic impairment or those taking higher doses of either drug."
"Paroxetine, a potent inhibitor of CYP2D6, can increase plasma concentrations of desloratadine, which is partially metabolized by CYP2D6. This elevation in desloratadine levels may potentiate its antihistaminic effects and, more rarely, its cardiac adverse effects such as QT prolongation. Although desloratadine has a low propensity for QT prolongation, the additive serotonergic effects are unlikely, but the interaction is primarily pharmacokinetic, leading to increased exposure and potential dose-related adverse events."
"The coadministration of methadyl acetate and desloratadine may lead to additive QT interval prolongation due to their respective cardiac repolarization effects. Methadyl acetate, as a µ-opioid receptor agonist and known QT-prolonging agent, increases the risk of torsade de pointes and other ventricular arrhythmias. Desloratadine, an antihistamine, possesses weak blocking activity of the hERG potassium channel, which can further potentiate the QT prolongation when combined, resulting in increased risk of life-threatening cardiac arrhythmias, especially in patients with pre-existing risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs BONTRIL PDM, answered by our medical review team.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is a Sympathomimetic that works by Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.. BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and BONTRIL PDM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is: One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.. The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and BONTRIL PDM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is classified as Category A/B. Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester;. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.